BioMedNewsBreaks Archive - Page 213 of 233

TuesdayNov 10, 2020 1:10 pm

BioMedNewsBreaks – Antibe Therapeutics Inc. (TSXV: ATE) (OTCQB: ATBPF) Graduates to the TSX

Antibe Therapeutics (TSXV: ATE) (OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced its receipt of final approval from the Toronto Stock Exchange (“TSX”) to list its common shares on the TSX. According to the update, Antibe’s shares will commence TSX trading under the company’s existing ticker symbol “ATE” at market open on Thursday, November 12, 2020. “We are excited to graduate to the TSX, as it represents a further step in reaching the broader investment community while increasing liquidity for our shareholders,” said Dan Legault, Antibe’s…

TuesdayNov 10, 2020 11:35 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (“SAB”). According to the update, Dr. Gittes is the inventor of GNPX’s licensed diabetes gene therapy technology that is currently in development and serves as the chief of pediatric surgery and surgeon-in-chief emeritus at the UPMC Children’s Hospital of Pittsburgh. “We are delighted to have Dr. Gittes join our Scientific Advisory Board as Genprex continues to advance its diabetes program,” said Rodney Varner, Genprex’s president and chief…

TuesdayNov 10, 2020 11:12 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters LOI with Asymchem for MS1819 Development, Production

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced its entry into a binding letter of intent (“LOI”) with Asymchem, a leading global contract development and manufacturing service (“CDMO”) provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency. Under the agreement, Asymchem will implement fermentation, verify protein expression and ultimately fine-tune the technology suitable for production of MS1819. Asymchem will be responsible for sourcing all materials required for the program under Current Good Manufacturing Practice (“cGMP”) regulatory conditions. “With a fairly competitive landscape for CDMOs,…

TuesdayNov 10, 2020 10:41 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Selected to Present at Upcoming Investor Conferences

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is slated to present at two upcoming investor conferences. Representing LexaGene at the conferences will be founder and CEO Jack Regan. Regan will be a presenter at the Investor Summit Group Conference held Nov. 18, 2020, at 1:30 p.m. and at the Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum scheduled for Nov. 19, 2020, at 10 a.m. EST; additional information about these conferences and Regan’s presentations is available on the event page of LexaGene’s website.“This is an excellent opportunity for the Company…

MondayNov 09, 2020 9:46 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update at 4:30 p.m. ET on Nov. 12, 2020, to discuss the clinical trial design for its upcoming Phase 2 U.S. trial for Berubicin. CNSP’s lead drug candidate – Berubicin – is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer, currently considered incurable. Robert LeBoyer, managing director of equity research at Ladenburg Thalmann & Co. Inc., will moderate the discussion.…

FridayNov 06, 2020 9:16 am

BioMedNewsBreaks – Turning Point Therapeutics Inc. (NASDAQ: TPTX) Secures $460M in Underwritten Public Offering

Turning Point Therapeutics (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, has closed an underwritten public offering of 5,287,357 shares of its common stock, including 689,655 additional shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Turning Point Therapeutics secured approximately $460 million in gross proceeds, with each of the shares sold at the public offering price of $87.00. Roth Capital Partners acted as co-manager for the offering. For more information, visit the company’s website at: www.TPTherapeutics.com About Turning Point Therapeutics Turning Point is a…

ThursdayNov 05, 2020 12:30 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with a high unmet medical need, today announced the appointment of Dr. Khalid Islam to its board of directors. Dr. Islam was the chairman and CEO of Gentium S.p.A. (a Nasdaq-listed company; 2009-2014) where he led its transition to a profitable company that subsequently sold for US$1 billion. In addition, he is currently an advisor to the venture group Kurma Biofund (Paris), the chairman of the board for Fennec Pharmaceuticals Inc. (NASDAQ: FENC), Gain Therapeutics Inc. and Minoryx Therapeutics SL, and…

ThursdayNov 05, 2020 11:55 am

BioMedNewsBreaks – Applied UV Inc. (NASDAQ: AUVI) Enters Non-Binding LOI to Acquire Airocide(TM) System for Airborne Pathogen Reduction

Applied UV (NASDAQ: AUVI), an infection prevention technology company that applies the power of ultra violet C ("UV-C") light utilizing its patented devices to destroy pathogens, today announced its entry into a non-binding letter of intent ("LOI") with Akida Holdings LLC. In addition to its exclusive joint distribution and licensing agreement with Akida Holdings, the LOI is to explore the possibility of acquiring certain key assets of Akida. This includes Akida’s rights to the manufacture and sale of the Airocide(TM) System of patented, air purification technologies, which may aid in the reopening of the global economy with applications in the…

WednesdayNov 04, 2020 12:37 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Report Q3 2020 Financial Results, Host Conference Call

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced that it will release financial results for its second quarter ended September 30, 2020, on Thursday, Nov. 12, 2020, as well as host a conference call at 9:00 a.m. Eastern Time. According to the update, Erez Raphael, chief executive officer, Rick Anderson, president and general manager of North America and Zvi Ben-David, chief financial officer will host the call. Interested parties may register via the webcast link and join the call by dialing 844-369-8770 (Toll-Free) or 862-298-0840 (International) and providing the following conference ID: DarioHealth Third Quarter…

WednesdayNov 04, 2020 9:37 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, was featured in an institutional research report by Craig-Hallum Capital Group LLC. The report discusses Craig-Hallum’s research coverage of PCSA and details the company’s experienced management team and its ownership rights to five programs that are de-risked by existing data. The piece reads, “By early next year, PCSA expects to begin three clinical trials – PCS499 in Phase IIb to treat necrobiosis lipoidica (‘NL’), PCS6422 in Phase 1b as an adjunct to the chemotherapy 5-FU,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Antibe Therapeutics Inc. (TSXV: ATE) (OTCQB: ATBPF) Graduates to the TSX

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters LOI with Asymchem for MS1819 Development, Production

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Selected to Present at Upcoming Investor Conferences

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar

BioMedNewsBreaks – Turning Point Therapeutics Inc. (NASDAQ: TPTX) Secures $460M in Underwritten Public Offering

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam

BioMedNewsBreaks – Applied UV Inc. (NASDAQ: AUVI) Enters Non-Binding LOI to Acquire Airocide(TM) System for Airborne Pathogen Reduction

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Report Q3 2020 Financial Results, Host Conference Call

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search